New hope for older lymphoma patients: gentler, smarter treatment on the horizon?

NCT ID NCT06765317

Recruiting now Disease control Sponsor: Memorial Sloan Kettering Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jul 23, 2026 · Updated 3 times

Summary

This study is testing a new treatment for older adults (65 and up) with diffuse large B-cell lymphoma (DLBCL) or similar aggressive lymphomas. The treatment combines a targeted immunotherapy drug called glofitamab with standard chemotherapy, aiming to improve cancer remission while reducing side effects. About 42 participants will receive this combination, and researchers will track how many achieve a complete response.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Glofitamab (a drug that helps the immune system attack cancer cells) combined with polatuzumab, obinutuzumab, and standard chemotherapy (rituximab, cyclophosphamide, doxorubicin, prednisone)
What this could lead to: If successful, this could offer a more effective and less toxic first treatment for older adults with aggressive B-cell lymphoma, potentially improving survival and quality of life.
What could go wrong: This is a small, early-phase trial (42 participants) with no control group, so results may not be definitive. The drug combination may still cause significant side effects, and not all patients may respond.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIFFUSE-LARGE B-CELL LYMPHOMA (DLBCL) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

diffuse large B-cell lymphoma high grade B-cell lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DIFFUSE-LARGE B-CELL LYMPHOMA (DLBCL) HIGH-GRADE B-CELL LYMPHOMA

Contacts and locations

Locations

Hackensack Meridian Health (Data collection only)
RECRUITING

Hackensack, New Jersey, 07601, United States
Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities)
RECRUITING

Basking Ridge, New Jersey, 07920, United States
Memorial Sloan Kettering Bergen (Limited Protocol Activities)
RECRUITING

Montvale, New Jersey, 07645, United States
Memorial Sloan Kettering Cancer Center (All Protocol Activities)
RECRUITING

New York, New York, 10065, United States
Memorial Sloan Kettering Cancer Center Suffolk - Commack (Limited Protocol Activities)
RECRUITING

Commack, New York, 11725, United States
Memorial Sloan Kettering Monmouth (Limited Protocol Activities)
RECRUITING

Middletown, New Jersey, 07748, United States
Memorial Sloan Kettering Nassau (Limited Protocol Activities)
RECRUITING

Rockville Centre, New York, 11553, United States
Memorial Sloan Kettering Westchester (All Protocol Activities)
RECRUITING

Harrison, New York, 10604, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.